LifeMD, Inc. (LFMD) LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical device, and custom-compounded topical treatments for both male and female hair loss. RexMD serves as a men's telehealth brand, providing virtual medical treatment from licensed providers for a wide array of male-specific health needs. LifeMD Primary Care offers a personalized, subscription-based virtual primary care solution, addressing routine, urgent, and chronic health management requirements. This mobile-centric platform integrates remote consultations, medication management, diagnostic services, and imaging referrals. Cleared is a telehealth service dedicated to offering personalized therapies for allergic, asthmatic, and immunological conditions. Nava MD stands as a skincare and tele-dermatology brand catering specifically to women, facilitating virtual access to dermatologists and other specialists for medical treatment. Additionally, the company provides PDFSimpli, a cloud-based software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents online. LifeMD distributes its offerings directly to individuals, via its own e-commerce channels, and through collaborations with external partners. Originally established in 1994 as Conversion Labs, Inc., the company rebranded to LifeMD, Inc. in February 2021 and is headquartered in New York City.
Sector: Services-Offices & Clinics of Doctors of Medicine
Industry: Medical - Healthcare Information Services
LifeMD, Inc. NASDAQ:LFMD Healthcare · Medical - Healthcare Information Services
Mkt Cap $86.76M
EV -
SI 18.0%
Net Cash/Sh -
AH After hours +0.00% $1.79
Prev close $1.85 -2.97%Close $1.79 0.00% Now $1.79 VOL 950K $ Vol $1.7M RVOL 0.80x
Mkt Cap $86.76M
EV -
VOL 950K sh
$ Vol $1.7M
RVOL 0.80×
SI 18.0%
Net Cash/Sh -
Press Release ● Major
LifeMD Reports Third Quarter 2026 Results
LifeMD reported Q3 2026 revenue of $44.6 million, down about 7% year-over-year and below guidance, with a GAAP net loss from continuing operations of $0.11 per share. Adjusted EBITDA improved roughly $3.1 million sequentially to a loss of about $0.4 million, driven by a 34% sequential cut in selling and marketing expense, while active subscribers grew 13% YoY to approximately 350,000. However, the company cut full-year 2026 guidance to revenue of $188-191 million (from $205.5-212.5 million) and adjusted EBITDA of negative $12.6M to negative $10.6M (from negative $6.0M to breakeven).
• 5d ago AI analysis › Press Release
LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026
LifeMD rescheduled its third quarter 2026 earnings release and conference call to Thursday, November 12, 2026. The press release is expected on or around 4:05 p.m. ET, followed by the call at 4:30 p.m. ET with a live and archived webcast available.
• 10d ago AI analysis › Press Release
LifeMD expands access to Lilly’s self-pay GLP-1 medicines, enabling option to dispense and ship directly to patients nationwide
LifeMD announced an arrangement with Eli Lilly enabling its affiliated pharmacy to directly dispense and ship Lilly's self-pay GLP-1 medicines, Zepbound and Foundayo, to eligible patients nationwide. Prescriptions from LifeMD-affiliated providers are fulfilled by LifeMD's licensed mail-order pharmacy at Lilly's established self-pay cash price, with no insurance billing.
• 12d ago AI analysis › Press Release
LifeMD to Report Third Quarter 2026 Financial Results on November 9
LifeMD will report Q3 and nine-month 2026 financial results before market open on November 9, 2026. The company will host a conference call and webcast at 8:30 a.m. Eastern the same day.
• 28d ago AI analysis › Press Release
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD's board declared a quarterly cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock. Payment is set for October 15, 2026, to holders of record at the close of business on October 2, 2026.
• 1mo ago AI analysis › Press Release ● Major
AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD
AT&T becomes the first and only carrier to offer eligible wireless and fiber customers free access to LifeMD's virtual care and pharmacy platform through an exclusive collaboration, with the $19 monthly membership fee waived -- a $228 annual value. More than 100 million AT&T customers are eligible for the benefit, delivered through AT&T's &More program; rollout begins with 29 million customers across 11 states and expands nationwide in January 2027. LifeMD monetizes via usage rather than membership fees, with visits starting at $29 for message-based care, $49 for video visits, and $79 for specialty care, plus pharmacy revenue.
• 2mo ago AI analysis › Press Release
UPDATE - LifeMD Reports Second Quarter 2026 Results
LifeMD reported Q2 revenue of $47.3 million, within guidance, while adjusted EBITDA loss improved 21% sequentially to $3.5 million on gross margin expansion to 89%. Management revised full-year 2026 revenue guidance down to $205.5 million to $212.5 million and adjusted EBITDA to a range of a $6 million loss to breakeven, lowering prior expectations due to the strategic shift to branded therapies.
• 3mo ago AI analysis › Press Release ● Major
LifeMD Reports Second Quarter 2026 Results
LifeMD reported Q2 2026 revenue of $47.3 million, within guidance range, while adjusted EBITDA loss improved 21% sequentially to approximately $3.5 million. The company revised full-year 2026 guidance downward to revenue of $205.5-212.5 million and adjusted EBITDA of negative $6 million to breakeven, citing a strategic transition to branded GLP-1 therapies and longer-duration memberships. Total active subscribers grew 20% year-over-year to approximately 356,000, with weight management program subscribers reaching 108,000 at quarter end.
• 3mo ago AI analysis › Press Release
LifeMD to Report Second Quarter 2026 Financial Results on August 5
LifeMD announced it will report its financial results for the second quarter of 2026 after the market close on August 5. A conference call to discuss the results for the three and six months ended June 30 is scheduled for 4:30 p.m. Eastern time on the same day.
• 3mo ago AI analysis › Press Release
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD declared a quarterly cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock.
• 4mo ago AI analysis › Press Release
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
LifeMD entered an exclusive co-marketing collaboration with Halozyme’s Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED, the only FDA-approved once-weekly subcutaneous testosterone auto-injector. The program is set to launch in July 2026 across 37 states, offering the treatment at a transparent all-inclusive price of approximately $249 per month that covers both medication and clinical care.
• 4mo ago AI analysis › Press Release
LifeMD Appoints Umesh Sripad as Chief Technology Officer
globenewswire.com • 5mo ago Press Release
LifeMD to Participate in Upcoming Investor Conferences
LifeMD announced that management will participate in two upcoming investor conferences in mid-May 2026. The company will present at the LD Micro Invitational XVI Conference on May 19 and hold one-on-one meetings at the B. Riley Securities Annual Investor Conference on May 20.
• 6mo ago AI analysis › Press Release ● Major
LifeMD Reports First Quarter 2026 Results
LifeMD reported Q1 2026 revenue of $50.2 million, beating company guidance, while gross margin expanded 420 basis points to 88%. Operational momentum was strong, with record quarterly net subscriber adds of over 42,000 driven by a 120% sequential increase in weight management sign-ups and 657% growth in Women's Health.
• 6mo ago AI analysis › Press Release
LifeMD to Report First Quarter 2026 Financial Results on May 6
LifeMD announced it will report financial results for the quarter ended March 31, 2026, after market close on May 6. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results.
• 6mo ago AI analysis › Press Release ● Critical
LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
globenewswire.com • 7mo ago 4 law-firm class-action alerts